Business · 1 sources covering this

US FDA Rejects Summit's China-Originated Lung Cancer Drug

The FDA issued a so-called Complete Response Letter saying that it can't approve Summit's application in its present form because the drug didn't help patients live longer in a statistically significant way.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·4h ago
US FDA Rejects Summit's China-Originated Lung Cancer Drug
The FDA issued a so-called Complete Response Letter saying that it can't approve Summit's application in its present form because the drug didn't help patients live longer in a statistically significant way.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/983d4943ed6997e241ff02fa2f811a6d4de8e109"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="US FDA Rejects Summit's China-Originated Lung Cancer Drug"></iframe>

US FDA Rejects Summit's China-Originated Lung Cancer Drug

How 1 sources are covering this

US FDA Rejects Summit's China-Originated Lung Cancer Drug

More from Business

Global supply chains may take 3-6 mths to normalise

Peak repo rate pegged lower at 6%, Dec hike on

Middle East crisis: Bahrain 'blocks' Tehran's strikes

Big 4 turn India's boom phase into biz opportunity

Reader

Trust & legal

Across the network